Plus Therapeutics Shares First Quarter 2026 Financial Results and Updates on REYOBIQ and CNSide Progress

May 15, 2026 - 17:39

HOUSTON, May 15, 2026 -- Plus Therapeutics, a healthcare company focused on precision diagnostics and radiopharmaceuticals for central nervous system cancers, reported its financial results for the first quarter ended March 31, 2026. The company also provided an update on key programs, including the REYOBIQ clinical trial and the commercial rollout of CNSide.

Management highlighted two main priorities for 2026: scaling up the commercial launch of CNSide and advancing the REYOBIQ clinical program. CNSide is a diagnostic test designed to detect and monitor cancer cells in the cerebrospinal fluid. The company has been working to expand access to the test at major cancer centers and hospitals across the United States.

On the REYOBIQ front, Plus Therapeutics continues to enroll patients in its clinical studies. REYOBIQ is an investigational radiopharmaceutical being developed for the treatment of leptomeningeal metastases, a serious complication where cancer spreads to the membranes surrounding the brain and spinal cord. The company noted that patient recruitment has been steady, and it expects to share additional data from the program later this year.

Financially, the company reported results consistent with its planned spending on research and development, as well as commercial activities. Plus Therapeutics ended the quarter with a cash position it believes is sufficient to fund operations into the near term, though the company may seek additional capital to support further growth.

The company's leadership expressed confidence in the direction of both programs and reiterated a commitment to bringing new options to patients with CNS cancers.